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would resume payment in 1997, but only
for a limited number ofpatients participat-
ing in a seven-year study to be conducted
by the National Institutes ofHealth.
HCFA's announcement stirred up
strong sentiments among medical profes-
sionals accustomed to hashing out the pros
and cons of new procedures among them-
selves. Many agree on the need for further
research. Others, however, dismiss the
study as a political move to cut costs. Lung
reduction surgery costs between $35,000
and $70,000.
Although often considered new, LVRS
dates back to the late 1950s, when
University of Maryland surgeon Otto
Brantigan performed the surgery on 33
patients. Brantigan theorized that emphy-
sema patients would breathe more easily
with smaller lungs. An emphysematous
lung expands as the disease breaks down
the walls in the spongy organ's air sacs.
Pressure from the distended lungs prevents
the diaphragm from pushing air out effec-
tively. By reducing the lungs' size,
Brantigan believed he could improve the
mechanics of the breathing muscles.
Unfortunately, he had no means of mea-
suring his patients' improvement. His pro-
cedure was largely forgotten until its recent
revival, led by Cooper at Barnes Hospital
in St. Louis.
Cooper typically splits his patients'
sternums and uses a scalpel to remove
20-30% ofeach lung. His first 20 patients
demonstrated a remarkable 82% increase
in their forced expiratory volume, the
amount ofair they can blow out. Seventy-
one percent were able to give up supple-
mental oxygen. Other surgeons report sub-
stantial improvements in at least two-
thirds of their LVRS patients. "Our
patients feel dramatically better and
breathe better," said John Chen, assistant
chief of cardiothoracic surgery at the
University of California-Irvine Medical
Center.
But what about the minority ofpatients
who fail to improve, and the 5-10% who
die? Will patients who have had the surgery
live any longer than those receiving tradi-
tional treatment with drugs and rehabilita-
tion? These are among the questions NIH
officials expect their study to answer. The
NIH's National Heart, Lung and Blood
Institute will manage the study, which is
slated to begin in 1997. Approximately 15
medical centers will be chosen to conduct
clinical trials. Approximately 3,000 patients
will participate. All will receive intensive
pulmonary rehabilitation and drug therapy.
Half, chosen at random, then will undergo
LVRS. Researchers will compare the
progress ofthe two groups.
Those who support the study point out
the need for more data. "We should know
up front who improves and who does not,"
saidJonathon Truwit, interim division chief
of pulmonary and critical care medicine at
the University ofVirginia in Charlottesville.
"Ifwe're setting these patients' clocks back,
let's find outhowfarback."
Pulmonologist and ethicist MarkTonelli
of the University ofWashington in Seattle
pointed out the government's success in reg-
ulating the pharmaceutical industry. "Ifthis
were a new drug, instead of a new type of
surgery, the Food and Drug Administration
would require extensive testing," he said. "I
think thestudy is agoodmodel."
Critics object to the random selection
that will deny surgery to half the candi-
dates. They say drugs and rehabilitation
have never produced the dramatic improve-
ments seen in some LVRS patients. "We
see this as a government ploy to hold back
expenses," said Rodney Landreneau, head
of thoracic surgery at Allegheny General
Hospital in Pittsburgh.
HCFA's Sheingold countered, "We do
not base our decisions on cost. We base our
decisions on effectiveness. However, we're
all forced to assure the highest quality of
care while containing costs." Sheingold
added that the LVRS study may be just a
hint offuture government oversight ofsur-
gical procedures. "HCFA and the NIH are
looking into studying other areas, including
kidney/pancreas transplants," he said. "This
is a long overdue marriage of the payment
agency and the best scientific agency to pro-
vide data aboutwhatworks in health care."
Promising Lung Cancer Vaccine
An antibody developed by researchers at
Memorial Sloan-Kettering Cancer Center
(MSKCC) appears to prolong the lives of
patients with small cell lung cancer.
Patients who received injections containing
the antibody BEC2 and Mycobacterium
bovis, a strain of bacteria that stimulates
the immune system, were found to live
longer than patients who received only the
standard treatment for small cell lung can-
cer, which is chemotherapy with or with-
out radiation. Small cell lung cancer is usu-
ally fatal, with a 15-20% long-term sur-
vival rate for patients in whom the cancer
is contained to the chest, and only a 0-5%
long-term survival rate for those in whom
the cancer has spread beyond the chest.
The current median survival period, for
patients diagnosed with small cell lung
cancer, is 7-14 months.
To create BEC2, the researchers emu-
lated the structure of GD3 ganglioside, a
nonprotein molecule found in certain can-
A shot in the lungs. A new antibody may help
patients with small cell lung cancer live longer.
cer cells, such as small cell lung and
melanoma. GD3 is not recognized by the
body as a foreign molecule and therefore
does not usually trigger an immune
response, says Stefan Grant, an attending
physician at MSKCC and co-principal
investigator of the project to develop the
antibody. The researchers found that
BEC2 is recognized as foreign and, because
their structures are similar, stimulates the
production of antibodies against both
BEC2 and GD3. The antibodies signal the
immune system to destroy the cells con-
taining GD3 and BEC2, thus eliminating
the cancer.
MSKCC researchers conducted a clini-
cal trial on eight patients with small cell
lung cancer who had received chemothera-
py. The researchers administered the vac-
cine to the participants five times during a
period of 10 weeks. Six ofthe participants
completed the immunizations and were
evaluated, and four ofthese were found to
be free of the cancer and healthy three
years after their diagnoses.
The control group for this study con-
sisted of34 patients who had received simi-
lar chemotherapy at MSKCC. The median
survival for this group was 16.2 months,
whereas the median survival for the group
treated with BEC2 was more than 36
months. The study was presented at the
American Society of Clinical Oncology
annual meeting in May in Philadelphia.
The only side effect seen thus far is a
local reaction at the site of the injections,
which is manifested by inflammation and
leaves ascar, said Grant. MSKCC researchers
are now planning a larger study to test the
vaccine. "We are planning a large random-
ized phase-3 trial, which we anticipate [to be
conducted] towards the middle ofnextyear,"
Grant said. The study will involve more
patients and alarger control group.
Although the vaccine has not yet been
thoroughly tested, MSKCC researchers are
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optimistic. "I do feel positive, but we
acknowledge that these results are prelimi-
nary," Grant said. "We consider the results
extremely encouraging, but as enthusiastic
as we are, we all agree that we have not
proven [the vaccine's efficacy]." Grant said
that from a scientific standpoint, "only a
rigorously controlled trial" can prove the
effectiveness ofthevaccine.
The researchers are also hoping to use
the vaccine to treat melanoma. Preliminary
tests on patients with melanoma, led by
Paul Chapman ofthe dinical immunology
service at MSKCC, have been promising,
and a phase-3 trial is being planned, Grant
said.
Climate Change Researchers
Capture Tyler Prize
Three scientists whose work has docu-
mented more than 150,000 years ofglobal
climate change through the collection and
analysis ofglacier and polar ice have been
awarded the 1996 Tyler Prize for
Environmental Achievement. Willi
Dansgaard of the University of Copen-
hagen, Claude Lorius of the French
Institute of Polar Research and Tech-
nology, and Hans Oeschger of the
University of Bern shared a cash prize of
$150,000 and received gold medallions at
an awards dinner in LosAngeles.
Preserved within the great polar ice
caps is a remarkable record of the earth's
climate extending back hundreds of thou-
sands ofyears. Encased within the caps are
carbon dioxide and other gases, the dust of
numerous volcanic eruptions, evidence of
fierce global storms, and other traces ofcli-
mate change deposited during the span of
human existence.
"The composition of the ice itself tells
us about the temperature and atmospheric
conditions at the time the icewas formed,"
said Dansgaard. "So going deep into the
ice is like sticking a thermometer back-
wards in time." Searching for clues to the
earth's dimatic history through the study
of ancient ice was a revolutionary idea
when first proposed in the 1950s. Today,
it is the foundation of global climate
research. "Data from this work is used in
virtually all scientific studies and reports
about global warming to emphasize the
potential of atmospheric pollution to
adversely affect climate," said Robert P.
Sullivan, chair ofthe Tyler Prize Executive
Committee, which annually selects the
prizewinners.
The first polar deep ice core drilling
field expedition took place in 1966 in
Greenland. Since that time, additional
samples have been retrieved from Norway
andAntarctica. Drilling, involving interna-
tional teams ofscientists, takes place under
some of the most extreme weather condi-
tions on earth. The cores are less than 4
inches in diameter and can measure more
than a mile in length.
Once removed from the field, it often
takes decades of laboratory analysis to
unlock the oxygen isotopes and other
traces of ancient atmospheres trapped for
millennia in the ice. The result of the
researchers' painstaking work is a detailed
look back in time. Ofparticular interest to
environmental scientists has been the
reconstruction ofatmospheric carbon diox-
ide and methane levels during the last 300
years, which shows a strong relationship
between global climate and the chemical
composition of the atmosphere. This data
provides the most dramatic and convincing
evidence ofglobal warming tied to human
activities.
The Tyler Prize was established in
1973 by Los Angeles philanthropists John
and Alice Tyler as an international award
honoring significant scientific achieve-
ments in all disciplines of environmental
research and environmental protection.
Through their work, Tyler laureates have
focused worldwide attention on environ-
mental problems and motivated effective
action toward solutions. Three past Tyler
Prize winners have subsequently been
awarded the Nobel Prize in Chemistry.
The 11-member Tyler Prize Executive
Committee comprises esteemed environ-
mental scientists, several ofwhom are past
Tyler Prize recipients. The Tyler Prize is
administered by the University of
Southern California.
Assessing Free Radical Damage
Free radicals have developed a bad reputa-
tion, in the scientific and popular press but
recent research shows how difficult a causal
relationship between free radicals and dis-
ease may be to prove. Free radicals are
unstable oxygen molecules that can inter-
act with proteins, carbohydrates, lipids,
and DNA, and thereby can have diverse
effects on cellular function. Although some
evidence points in the direction offree rad-
icals as a culprit in a multitude ofdiseases,
including cancer, cardiovascular disease,
and Alzheimer's disease, a direct causal
relationship in human beings has yet to be
established. A primary reason for this is
that the generation of free radicals in
human beings has been difficult to mea-
sure. Free radical damage has been statisti-
cally inferred, measured by in vitro testing,
and implicated in autopsy results, but
never established in living humans. This
has also made it "difficult to identify drugs
or vitamins that may act as antioxidants to
combat the effect of free radicals, and
therefore, to identify appropriate doses
which could be assessed in clinical trials,"
says Garret FitzGerald, chairman of the
department ofpharmacology and a profes-
sor of cardiovascular medicine at the
University of Pennsylvania Medical
Center, Philadelphia.
However, in a recent study, FitzGerald
and his colleagues were able to noninva-
sively measure the effects offree radicals on
the human body. The study was reported
in the 1 July 1996 issue of Circulation, a
journal oftheAmerican HeartAssociation.
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